Léa Floquet

Founded in 1995, Swiss Re Capital Markets Corp. is a registered broker/dealer located in New York City. The firm is a subsidiary of Swiss Reinsurance Co. Swiss Re Capital Markets Corp. is committed to the development of a market for liquid, transparent and tradable insurance-linked risk products, leveraging their re/insurance and capital markets experience.

HERMAL Kurt Herrmann GmbH & Co. oHG provides skin care products. The company develops products for the treatment of skin related diseases. It is a dermatological company with marketing and sales departments throughout Europe and a production unit based in Germany. HERMAL Kurt Herrmann was founded in 1946 and is headquartered in Reinbek, Germany.

Chr. Hansen A/S engages in bioscience research that develops natural solutions for the food, nutritional, pharmaceutical and agricultural industries. It also develops and produces cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed. The company was founded by Christian D. A Hansen in 1874 and is headquartered in Horsholm, Denmark.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.

CIC Market Solutions SA is the broker-dealer subsidiary of Crédit Industriel et Commercial SA, ultimately owned by Groupe Crédit Mutuel in France. Headquartered in Paris, the firm was founded in 1991 and handles commercial market activities for corporate and professional investor clients of Crédit Mutuel Alliance Fédérale group. CIC Market Solutions also provides primary equity and bond market services and execution and sale on the capital markets.

TopoTarget UK Ltd. engages in the discovery and development of drugs and therapies to treat cancer. It develops anti-cancer drugs for molecular mechanisms associated with the cell cycle, chromatin control and DNA damage. The company was founded in 2002 and is headquartered in Oxford, the United Kingdom.

Kepler Cheuvreux SA is an independent broker/dealer headquartered in Paris, France. The firm was founded by Laurent Quirin in 1997. Kepler Cheuvreux provides execution services to institutional investors. It supports equities, fixed income, derivatives, ETFS, and convertible bonds across Europe, America and Asia.

Sanofi-Aventis Deutschland GmbH engages in the development, manufacture, and packaging of medicines, as well as pharmaceutical products. It also focuses on the research into the causes of diseases and the search for its drug treatment. The company was founded in 2004 and is headquartered in Frankfurt, Germany.

INSERM Transfert Initiative SAS is a venture capital fund that invests in companies located in France. It targets startups from the life sciences and biotechnology sectors, developing new medical practices with a strong intellectual property. It invests between €1 million and €3 million per company during mostly at pre-seed, seed and early-stages.

Lundbeck SAS is a pharmaceutical laboratory, which focuses on neurology and psychiatry. The company was founded in 1992 and is headquartered in Paris La Defense, France.

BioNet Pharma GmbH engages in development of medical devices, pharmaceutical drugs and regenerative medical products. Its pipeline covers pre-clinical and clinical development programs in osteoarthritis, inflammatory joint disease, cartilage injury, and severe gingival inflammation. The company is headquartered in Martinsried, Germany.

Part of Sanofi, Hoechst GmbH is a German company that manufactures and sells drugs. The company is based in Frankfurt, Germany. The CEO of the company is Fabrizio Guidi.

Avillion LLP operates as a drug development company that focuses on clinical development and approval of late stage pharmaceutical products and candidates. It offers global clinical trial, and global regulatory services. The firm serves pharmaceutical and biotechnology companies. The company was founded in 2012 and is headquartered in London, the United Kingdom.

Quadrille Capital SAS (Quadrille Capital) is an independent private equity firm founded in 2007. The firm is headquartered in Paris, France with an additional office in United States.

BliNK Biomedical SAS is a French company that specializes in cutting-edge technology for identifying rare antibody-secreting cells from humans and other species. The company is based in Marseille, France. The company's technology is based on validated platforms, isaac and vivascreen, which provide a highly efficient and deep mining process. The CEO of the company is Jack Elands.

Founders Future SAS is an independent Venture Capital firm with headquarters in France, Paris. Founders Future was founded in 2017 by Marc Ménasé.

Global Antibiotic Research & Development Partnership is a Swiss company that is working to combat antibiotic resistance. The non-profit company is based in Geneva, Switzerland. Antibiotic resistance occurs when bacteria no longer respond to treatment, and millions of people suffer from this every year. The company is developing a new initiative called SECURE, which aims to provide access to essential antibiotics and prepare for and respond to pandemics.

Emergence Therapeutics AG is biopharmaceutical company. It develops novel antibody drug conjugate. The company was founded by Jack Elands and Xavier Preville and is headquartered in Duisburg, Germany.

Founded in 2011, Health Economics & Outcomes Research Ltd. is a British management consulting company that provides consulting services. The company is based in Cardiff, UK and is part of HEOR Holdings Ltd.

Part of Bavarian Nordic A/S, Bavarian Nordic GmbH engages in research and development in biotechnology for cancer and infectious diseases. The company is based in Martinsried, Germany. The German company was founded in 2014. Paul Chaplin has been the CEO of the company since 1999.